vs
CytomX Therapeutics, Inc.（CTMX）与FVCBankcorp, Inc.（FVCB）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是FVCBankcorp, Inc.的1.1倍（$18.7M vs $16.9M），FVCBankcorp, Inc.同比增速更快（4377.5% vs -25.7%），FVCBankcorp, Inc.自由现金流更多（$23.8M vs $-15.8M），过去两年FVCBankcorp, Inc.的营收复合增速更高（586.6% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
FVCBankcorp是总部位于美国弗吉尼亚州的银行控股公司，旗下运营社区银行FVCbank，面向大西洋中部地区的中小企业、专业人士及个人客户提供存款、贷款、按揭、财富管理等各类个人及商业银行金融服务。
CTMX vs FVCB — 直观对比
营收规模更大
CTMX
是对方的1.1倍
$16.9M
营收增速更快
FVCB
高出4403.2%
-25.7%
自由现金流更多
FVCB
多$39.6M
$-15.8M
两年增速更快
FVCB
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $16.9M |
| 净利润 | $-154.0K | — |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 43.7% |
| 净利率 | -0.8% | — |
| 营收同比 | -25.7% | 4377.5% |
| 净利润同比 | 97.6% | — |
| 每股收益（稀释后） | — | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXFVCB
| Q4 25 | — | $16.9M | ||
| Q3 25 | — | $416.0K | ||
| Q2 25 | $18.7M | $15.8M | ||
| Q1 25 | $50.9M | $382.0K | ||
| Q4 24 | $38.1M | $378.0K | ||
| Q3 24 | $33.4M | $412.0K | ||
| Q2 24 | $25.1M | $415.0K | ||
| Q1 24 | $41.5M | $359.0K |
净利润CTMXFVCB
| Q4 25 | — | — | ||
| Q3 25 | — | $5.6M | ||
| Q2 25 | $-154.0K | $5.7M | ||
| Q1 25 | $23.5M | $5.2M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $4.7M | ||
| Q2 24 | $-6.5M | $4.2M | ||
| Q1 24 | $13.8M | $1.3M |
营业利润率CTMXFVCB
| Q4 25 | — | 43.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | 45.9% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
净利率CTMXFVCB
| Q4 25 | — | — | ||
| Q3 25 | — | 1341.1% | ||
| Q2 25 | -0.8% | 36.0% | ||
| Q1 25 | 46.2% | 1352.1% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 1133.3% | ||
| Q2 24 | -26.0% | 1001.2% | ||
| Q1 24 | 33.3% | 373.3% |
每股收益（稀释后）CTMXFVCB
| Q4 25 | — | $0.31 | ||
| Q3 25 | — | $0.31 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | — | $0.28 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | — | $0.25 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $253.6M |
| 总资产 | $175.1M | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXFVCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
股东权益CTMXFVCB
| Q4 25 | — | $253.6M | ||
| Q3 25 | — | $249.8M | ||
| Q2 25 | $119.9M | $243.2M | ||
| Q1 25 | $25.0M | $242.3M | ||
| Q4 24 | $-456.0K | $235.4M | ||
| Q3 24 | $-23.5M | $230.8M | ||
| Q2 24 | $-31.2M | $226.5M | ||
| Q1 24 | $-31.7M | $220.7M |
总资产CTMXFVCB
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $175.1M | $2.2B | ||
| Q1 25 | $98.5M | $2.2B | ||
| Q4 24 | $120.5M | $2.2B | ||
| Q3 24 | $139.0M | $2.3B | ||
| Q2 24 | $159.2M | $2.3B | ||
| Q1 24 | $184.7M | $2.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $23.9M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $23.8M |
| 自由现金流率自由现金流/营收 | -84.6% | 140.7% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $40.0M |
8季度趋势，按日历期对齐
经营现金流CTMXFVCB
| Q4 25 | — | $23.9M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.0M | $5.4M | ||
| Q4 24 | $-19.9M | $18.2M | ||
| Q3 24 | $-20.7M | $4.7M | ||
| Q2 24 | $-19.5M | $1.6M | ||
| Q1 24 | $-26.0M | $7.2M |
自由现金流CTMXFVCB
| Q4 25 | — | $23.8M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.2M | $5.4M | ||
| Q4 24 | $-20.0M | $18.1M | ||
| Q3 24 | $-20.7M | $4.6M | ||
| Q2 24 | $-19.6M | $1.5M | ||
| Q1 24 | $-26.2M | $7.1M |
自由现金流率CTMXFVCB
| Q4 25 | — | 140.7% | ||
| Q3 25 | — | 1818.0% | ||
| Q2 25 | -84.6% | 20.8% | ||
| Q1 25 | -41.6% | 1413.6% | ||
| Q4 24 | -52.5% | 4786.0% | ||
| Q3 24 | -62.1% | 1121.8% | ||
| Q2 24 | -78.2% | 361.2% | ||
| Q1 24 | -63.1% | 1988.3% |
资本支出强度CTMXFVCB
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.2% | 37.3% | ||
| Q3 24 | 0.1% | 14.1% | ||
| Q2 24 | 0.4% | 12.8% | ||
| Q1 24 | 0.3% | 3.9% |
现金转化率CTMXFVCB
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | -0.89× | 1.05× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | -1.89× | 5.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FVCB
暂无分部数据
